Nirmatrelvir-Ritonavir Does Not Speed Up Alleviation of COVID-19 Symptoms
FRIDAY, April 5, 2024 -- For patients with confirmed COVID-19, nirmatrelvir-ritonavir is not associated with a shorter time to sustained alleviation of symptoms than placebo, according to a study published in the April 4 issue of the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 5, 2024 Category: Pharmaceuticals Source Type: news
Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients
(MedPage Today) -- Nirmatrelvir/ritonavir (Paxlovid) failed to shorten COVID-19 symptom duration among people at standard risk for severe COVID-19 and among vaccinated people with at least one risk factor for severe disease, according to final... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - April 3, 2024 Category: Infectious Diseases Source Type: news
Mission success: Ritonavir crystallization experiments conducted in space worked flawlessly
The metastable Form III was successfully crystallized in orbit and recovered after reentry to Earth WEST LAFAYETTE, Ind., March 22, 2024 /PRNewswire-PRWeb/ -- Improved Pharma and Varda Space Industries have published the first mission results in ChemRxiv in an article entitled Return of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 22, 2024 Category: Pharmaceuticals Source Type: news
COVID-19 Viral Load Rebound Can Occur After VV116, Nirmatrelvir-Ritonavir
WEDNESDAY, March 20, 2024 -- For patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound can occur after a standard five-day course of treatment with VV116 or nirmatrelvir-ritonavir, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 20, 2024 Category: Pharmaceuticals Source Type: news
Improved Pharma analyzing pharmaceuticals crystallized in space
Ritonavir crystallization experiments conducted on-board the world's first, fully autonomous, spacecraft built by Varda Space Industries WEST LAFAYETTE, Ind., Feb. 26, 2024 /PRNewswire-PRWeb/ -- Varda's satellite "Winnebago-1" was launched into space to demonstrate Varda's spacecraft &... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 26, 2024 Category: Pharmaceuticals Source Type: news
Why Aren't More Doctors Prescribing Paxlovid to High-Risk Patients?
(MedPage Today) -- Recent evidence is piling up that many people at high risk for severe COVID-19 don't receive nirmatrelvir/ritonavir (Paxlovid) -- or any outpatient antiviral treatment -- when diagnosed with a SARS-CoV-2 infection. MedPage... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - January 30, 2024 Category: Infectious Diseases Source Type: news
Simnotrelvir Shortens Time to Resolution of Symptoms in COVID-19
THURSDAY, Jan. 18, 2024 -- For adults with mild-to-moderate COVID-19, early administration of simnotrelvir plus ritonavir shortens the time to sustained resolution of symptoms, according to a study published in the Jan. 18 issue of the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2024 Category: Pharmaceuticals Source Type: news
Novel Antiviral Shortens COVID Illness in Outpatients, Reduces Viral Load
(MedPage Today) -- With oral simnotrelvir/ritonavir treatment in a vaccinated population, COVID-19 symptoms went away about 1.5 days earlier and SARS-CoV-2 viral loads fell, a Chinese placebo-controlled phase II/III trial found.
In patients with... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - January 17, 2024 Category: Infectious Diseases Source Type: news
NICE recommends more people have access to COVID-19 antiviral
More people should be eligible to receive the COVID-19 antiviral nirmatrelvir plus ritonavir (Paxlovid), according to new draft guidance from NICE. (Source: GP Online News)
Source: GP Online News - January 10, 2024 Category: Primary Care Tags: Clinical News Source Type: news
Paxlovid May Not Be Associated With Lower Long COVID Risk, Survey Suggests
(MedPage Today) -- Nirmatrelvir-ritonavir (Paxlovid) did not reduce the odds of developing long COVID in vaccinated, non-hospitalized adults, survey data showed.
About 16% of those treated with nirmatrelvir-ritonavir during acute infection with... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - January 5, 2024 Category: Infectious Diseases Source Type: news
SARS-CoV-2 Rebound Rate Similar With, Without Oral Antivirals
FRIDAY, Dec. 22, 2023 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rebound occurs at a similar rate for those receiving and not receiving oral antiviral treatment and for those receiving nirmatrelvir/ritonavir or placebo,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 22, 2023 Category: Pharmaceuticals Source Type: news
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
This report describes data from two randomized, double-blind clinical trials that investigated COVID-19 rebound following treatment with or without nirmatrelvir/ritonavir. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - December 21, 2023 Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Source Type: news
Zydus gets USFDA nod for antiviral drug used in HIV treatment
Zydus Lifesciences obtained final clearance from the USFDA for Darunavir Tablets, an antiviral medication used in treating HIV-1 infection. Darunavir, a protease inhibitor, restricts HIV-1 multiplication and is prescribed for adults and pediatric patients over three years old. Co-administration with Ritonavir and other antiretroviral agents is necessary. Manufactured in Ahmedabad, Gujarat, the medication holds significant market potential, recording USD 275 million in annual US sales. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 15, 2023 Category: Pharmaceuticals Source Type: news
How to Get Free Flu and COVID-19 Tests and Treatments
As we head into winter, health experts expect that cases of flu and COVID-19 will start to creep up. One piece of good news: if you do get sick, there’s a way to get tests and treatments for both—without paying a cent.
The National Institutes of Health (NIH), the Administration for Strategic Preparedness and Response and the Centers for Disease Control and Prevention have teamed up with digital health company eMed to create an at-home test-to-treat program that offers free tests for both flu and COVID-19, and, if you are positive, free telehealth visits and antiviral treatments that are sent to your home.
[t...
Source: TIME: Health - December 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Can Paxlovid Improve Long COVID Symptoms?
(MedPage Today) -- In this interview, Jeremy Faust, MD, editor-in-chief of MedPage Today, talks with Harlan Krumholz, MD, SM, of Yale School of Medicine in New Haven, Connecticut, about his ongoing study testing nirmatrelvir-ritonavir (Paxlovid... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - November 30, 2023 Category: Infectious Diseases Source Type: news
